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Rituximab is an anti-CD20 chimeric monoclonal antibody that depletes B-cells. Although 
initially developed as a treatment for haematological malignancies, rituximab is now 
frequently used in patients with autoimmune disorders, including inflammatory disorders of 
the central nervous system (CNS) associated with aquaporin-4 (AQP4)1 and myelin 
oligodendrocyte glycoprotein (MOG) antibodies2, and multiple sclerosis3.  
 
Biotti et al describe two patients with relapsing MOG-antibody associated disease who were 
treated with rituximab and developed late-onset neutropenia – a recognised complication of 
rituximab seen in both patients with cancer and autoimmune disease.4 Both patients 
presented with fever and grade 4 neutropenia (absolute neutrophil count < <0.5 x 109/L) 
several months after the last cycle of rituximab, requiring treatment with antibiotics and 
granulocyte-colony stimulating factor (G-CSF). Neutropenia recurred in one patient three 
months later, requiring further treatment with G-CSF. MRI-confirmed relapses occurred in 
both patients during episodes of neutropenia, despite adequate B-cell depletion with 
undetectable CD19 lymphocyte counts. One patient continued treatment with rituximab after 
resolution of the neutropenia, and the other patient was started on tocilizumab.  
 
The cases presented highlight two important clinical issues. Firstly, neurologists treating 
patients with neuroinflammatory disorders with B-cell depleting agents need to be aware of 
late-onset neutropenia. Although this complication is less common in the setting of 
autoimmune diseases than in patients with haematological malignancies4, severe (grade 
3/4) neutropenia can occur and increases the risk of infections. Febrile neutropenia is a 
medical emergency requiring urgent treatment with antibiotics and possibly G-CSF. Whether 
patients with late-onset neutropenia should continue treatment with rituximab is unclear. It 
may be possible to re-treat safely4, although enhanced full blood count monitoring should be 
considered. Secondly, these cases add to other recent reports of ongoing relapses in MOG-
antibody disease patients treated with rituximab2. Whether treatment failure in this setting is 
due to existing antibody-producing cells in the CNS despite peripheral B cell depletion, B-cell 
independent pathobiological mechanisms important in the pathogenesis of MOG-antibody 
associated diseases, or both is unclear. A better understanding of the neuroimmunologicial 
basis of MOG-antibody associated disease is required to develop more targeted treatment 
strategies. 
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